Moderna Pipeline Impacted? What Does it Mean Long Term?

Just came across some articles linking potential Moderna layoffs to changes in government funding for vaccine development. While the articles mention 'job cuts' and 'research staff drops,' it's a bit vague and doesn't specify if this is happening at Moderna directly or other companies in the space. Given Moderna's focus on mRNA technology and its ambitious pipeline beyond COVID vaccines (like RSV, flu, and even cancer vaccines), I'm wondering how these funding shifts are truly impacting their long-term research and development efforts. Are specific research arms being scaled back? Are promising early-stage projects being put on the back burner? For those working in biotech R&D, particularly in vaccine development, does this feel like a broader industry trend where innovation is being hampered by funding uncertainty? Curious to hear perspectives on how this might affect the pace of future therapeutic breakthroughs from companies like Moderna.